Abstract
Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.
MeSH terms
-
Amino Acid Substitution / genetics
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / pharmacology*
-
DNA Mutational Analysis
-
Drug Resistance, Viral*
-
Humans
-
Infant
-
Infant, Newborn
-
Male
-
Mutation, Missense
-
Palivizumab
-
Respiratory Syncytial Virus Infections / virology*
-
Respiratory Syncytial Virus, Human / drug effects*
-
Respiratory Syncytial Virus, Human / isolation & purification
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Palivizumab